The Coalition for Access to Prenatal Screening (CAPS) announced today that it has assembled a clinical advisory board to advise the coalition on medical and policy issues to help improve access to cell-free DNA (cfDNA)-based noninvasive prenatal testing (NIPT) for all pregnant women. Established in January 2017, CAPS is comprised of: Illumina, Inc. (ILMN); Counsyl, Inc.; Progenity, Inc.; Natera, Inc. (NTRA); and LabCorp® (LH) through its Integrated Genetics specialty laboratory.
submitted by /u/Steve_Johns
[link] [comments]
June 13, 2017 at 07:48PM
from /u/Steve_Johns
No comments:
Post a Comment